Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

kelihood to progress to type 2 diabetes compared to subjects receiving top-dose Qnexa and a two times greater likelihood than patients on mid-dose Qnexa.

 

Qnexa therapy was well tolerated, with no new adverse events observed in the second year of study. The most common side effects were upper respiratory infection, constipation, tingling, sinus infection, dry mouth and runny nose. There were no drug-related serious adverse events reported. The completion rate in SEQUEL was approximately 83% for both Qnexa doses and 86% for the placebo group. Discontinuations due to adverse events were 4.5% and 4.4% for the mid- and top-dose, respectively, and 3.1% for the placebo group.

About the SEQUEL Study

SEQUEL (OB-305) was a double-blind, placebo-controlled, three-arm, extension study. Patients continued receiving the same treatment assignment to which they had been randomized in the 56-week CONQUER study in a blinded fashion: either once-daily treatment with top-dose Qnexa (n=295), mid-dose Qnexa (n=153), or placebo (n=227). The SEQUEL study was a 52-week extension study for a subset of patients who completed the CONQUER study. The total study period was 108 weeks. SEQUEL included 676 obese or overweight patients, all of whom had two or more weight-related co-morbidities and an average baseline BMI of 36.1. Throughout the 108-week treatment period, all patients were advised to follow a modest lifestyle modification program including reduction of food intake by 500 calories per day.  The SEQUEL study was conducted at 36 sites in the United States.

Approximately 20% of SEQUEL subjects had type 2 diabetes at baseline and had been treated with lifestyle modifications alone or single-agent metformin. In this subgroup, weight loss associated with Qnexa had a favorable impact on glycemic control without a need for added oral hypoglycemic agents. In subjects without type 2 diabetes at baseline, the favo
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... NEWTOWN, Pa. , July 6, 2015 /PRNewswire/ ... services and technology provider, today announced that it ... retention firm, MediciGroup ® , Inc. (Medici).  The ... Access to Patients, LLC.  Medici also provides a ... finds missing patients globally.  Together with Medici, ...
(Date:7/6/2015)... , July 6, 2015 Hologic, Inc. (NASDAQ: ... to release its financial results for the third quarter ... the market closes.  In conjunction with the release, management ... p.m. Eastern Time. Interested participants may listen ... the United States ) or 719-325-4804 (for international ...
(Date:7/6/2015)... N.J. and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of Series E warrants to ... Series F warrants to purchase 2,191,781 shares of ...
Breaking Medicine Technology:BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories ... and Drug Administration (FDA) has approved Absorica™, a novel, ... the treatment of severe recalcitrant nodular acne. Through a ... RLI is expected to launch Absorica™ in the U.S. ...
... 2012  Janssen Therapeutics, Division of Janssen Products, LP, ... (FDA) has issued a Complete Response letter for ... 800mg tablet of PREZISTA® (darunavir). PREZISTA is ... 400mg tablets -- for the treatment of human immunodeficiency ...
Cached Medicine Technology:Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA 2FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 2FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 3FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 4FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 5FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 6FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet 7
(Date:7/6/2015)... ... July 06, 2015 , ... ... Spa industries, announces the return of its complimentary educational webinar series ... medical business leaders creates success for their clients through targeted marketing, sales, digital ...
(Date:7/6/2015)... ... 06, 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a ... at a CAGR of over 3.2 percent in the years to come to hit ... mainly spurred by an anticipated launch of a number of promising pipeline candidates and ...
(Date:7/6/2015)... ... , ... doTERRA, the leading global essential oils company, is pleased to announce ... the position as Director of the Hinckley Institute at the University of Utah, a ... Jowers states that he was ready for a new challenge, and out of many ...
(Date:7/6/2015)... ... ... Seedstock today announced Pierre Sleiman, founder and CEO of Go Green ... Conference – “Innovation and the Small Farmer” – to be held Nov. 3-4 San ... will explore solutions and methodologies that small farmers and entrepreneurs are developing to improve ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... MD Now, ... Monday, July 6. The newly constructed urgent care center will serve residents and visitors ... In addition to being MD Now’s 22nd South Florida location, the new facility will ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3
... new research, Atkins diet-low carbohydrate diet can increase the risks ... the production of a fatty acid in the gut , ... acid butyrate, which protects against colorectal cancer, is produced by ... Rowett Research Institute, in Aberdeen, found that the widely ...
... the rule themselves - and certainly so when it comes ... local authorities have sent notices to the Delhi High Court, ... for breeding mosquitoes, the carrier of the dreaded dengue and ... field visits they have found mosquito breeding grounds in the ...
... launching Stop AIDS in Children, a campaign that calls for ... half a million new infant HIV infections that occur worldwide ... the leaders of the world's eight most powerful countries had ... for prevention of mother-to-child transmission (PMTCT) services in the developing ...
... The British government took a step Wednesday toward offering vaccinations ... a measure that could be carried out by late next ... recommended the use of vaccines to guard against the human ... cases of cervical cancer. ,The Department of Health ...
... her current rehab stint pretty 'serious' and doesn't want to 'mess ... Girls' star said that the actress will be in the rehab ... time frame for her stay due to her work schedule. ... We don't know how much longer because of her work schedule, ...
... dozens of nurses who had blocked a main road in front ... The nurses had set up camp in the street in ... ,An AFP reporter saw several units of police in ... security forces cleared the street itself, the nurses managed to continue ...
Cached Medicine News:Health News:Notice Sent to Courts Asking Them to Stop Courting Mosquitoes 2Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Girls Could Be Vaccinated Against Cervical Cancer in Britain 2Health News:Polish Police Break Up Nurses' Pay Protest 2
Inquire...
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Inquire...
Medicine Products: